EP Patent

EP0966967A2 — Combination therapy of olanzapine (zyprexa) and fluoxetine (prozac) for treatment of bipolar disorder

Assigned to Eli Lilly and Co · Expires 1999-12-29 · 26y expired

What this patent protects

The invention provides methods and compositions for the treatment of Bipolar Disorder, Bipolar Depression or Unipolar Depression, all with or without psychotic features. This method employs a compound having activity as an atypical antipsychotic and a serotonin reuptake inhibitor…

USPTO Abstract

The invention provides methods and compositions for the treatment of Bipolar Disorder, Bipolar Depression or Unipolar Depression, all with or without psychotic features. This method employs a compound having activity as an atypical antipsychotic and a serotonin reuptake inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
EP0966967A2
Jurisdiction
EP
Classification
—
Expires
1999-12-29
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.